Skip to content

Advertising disclosure: We earn commissions from some of the products we link to. It never changes our scores or what we publish. Read the full disclosure

Tom’s Weight LossRankings

Understand treatment

GLP-1 medicines and off-label use: what the term means

Separate a drug’s approved uses from a clinician’s prescribing decision, and understand why compounded products belong in a different category.

By Tom's Weight Loss Rankings · Published · Updated · 4 min read

This article promotes CoreAge Rx and includes commercial links. Service claims are attributed to CoreAge Rx; medical and regulatory information is linked to its sources.

Tom’s Weight Loss Rankings is not a medical provider. Individual care decisions require a licensed clinician. This article does not report a clinical review or study of CoreAge Rx patients.

Advertising disclosure · Medical disclaimer

The quick answer

Off-label use means using an FDA-approved drug outside its approved labeling. It can involve a different condition, dose or way of giving the drug. The term does not turn a compounded product into an approved medicine. Start with the exact product and the purpose your clinician proposes.

Put the product and the proposed use on separate lines

An approval is attached to a particular medicine and its labeled uses. FDA explains off-label prescribing as use of an approved drug beyond that labeling. Clinicians generally may do this when they judge it medically appropriate; FDA has not determined safety and effectiveness for that unapproved use.

For a conversation with your prescriber, write the product name on one line and the condition being treated on the next. Add the form you would receive. “A GLP-1 for my health” leaves too much unspecified to tell which evidence or instructions apply.

Why Ozempic and Wegovy need their own labels

Ozempic and Wegovy contain semaglutide, but they have different approved indications. The current Ozempic prescribing information lists adult type 2 diabetes uses, including specified cardiovascular and kidney risk reduction. Weight management by itself is not an Ozempic indication.

The Wegovy label includes long-term weight reduction in adults with obesity, or overweight with a weight-related condition, with reduced-calorie eating and increased physical activity. Both tablets and injection have adult weight-management indications; injection also has an indication for adolescents aged 12 and older with obesity. The complete label includes other uses and limitations.

Imagine Nia, a fictional reader, hears that a friend takes Ozempic and asks whether every semaglutide prescription must be off-label for weight. The brand-specific labels answer that question more accurately than the ingredient name alone. Her friend’s prescription also does not tell Nia which treatment would suit her.

Ask what supports the particular proposal

The words “off-label” are a starting point for a discussion, not a rating of how good a treatment is. Ask the prescriber to identify the exact departure from the label and explain the evidence relevant to your situation. A confident product description cannot do that work for them.

A useful explanation would connect your treatment goal, the studies or clinical guidance being used, alternatives, remaining uncertainty and the plan for follow-up. If those pieces are unclear, request clarification before treating a general claim about GLP-1 medicines as a personal treatment plan.

A compounded prescription is a different approval question

FDA’s compounding FAQ distinguishes compounded preparations from FDA-approved drugs and approved generics. A compounded semaglutide preparation is therefore not simply a box of Ozempic being prescribed off-label. Having a prescription does not establish FDA approval of the supplied product.

When comparing two offers, keep “What is this product?” separate from “Why is it being prescribed for me?” Otherwise, an explanation about a clinician’s discretion can leave the product’s own approval status unanswered.

Apply the distinction to CoreAge Rx’s menu

CoreAge Rx’s product guide describes compounded semaglutide and tirzepatide, as well as a nonprescription GLP-1 Support supplement. Those descriptions identify different product categories. Neither a clinician’s review nor the shared GLP-1 wording makes the compounded products FDA-approved or the supplement a prescription medicine.

Use our CoreAge Rx profile for service context, then ask which exact preparation would be prescribed and why an approved option cannot meet your medical needs. Its intake instructions describe collecting health history, medications and allergies for provider review. Completing that form is not itself a prescription or a guarantee of treatment.

If you landed on a supplement offer instead, our guide to checking supplement evidence follows the claim from the label to the study. The short category comparison can help you organize several offers before a medical appointment.

Bring a short explanation back from the appointment

Leave space in your notes for the prescriber’s answers: the full product name, the intended use, any aspect outside approved labeling, why this approach fits your circumstances and when the plan will be reassessed. Record whom to contact if the prescription or supplied product differs from that explanation.

Do not use an off-label example from an article to change a dose, route or medicine yourself. This guide helps you interpret the terms in a treatment discussion; the actual instructions must come from the team responsible for your care.

Common questions

Does off-label mean that the medicine itself has no FDA approval?

No. Off-label describes a use outside an approved drug’s labeling. That is a separate issue from whether the product itself is approved.

Is compounded semaglutide an FDA-approved generic?

No. Compounded preparations do not have FDA approval. A comparison needs to identify the product actually supplied, not just the ingredient being advertised.

Can I use someone else’s GLP-1 instructions if the ingredient matches?

No. Their product, indication and prescribed regimen may differ. Ask your own prescriber or pharmacist for instructions matched to your prescription.

Sources and fact-checking

Sources checked 2026-09-09. CoreAge Rx pages support descriptions of its service; medical and regulatory sources support the educational context. Offers and availability can change.

  1. FDA: understanding off-label use
  2. DailyMed: Ozempic prescribing information
  3. DailyMed: Wegovy prescribing information
  4. FDA: compounding questions and answers
  5. FDA: unapproved GLP-1 concerns
  6. CoreAge Rx: product categories
  7. CoreAge Rx: medical intake